Roche’s Vabysmo Advantage Over Eylea Hard To See In Latest Head-To-Head

Both Drugs Dosed Monthly

 
• By Andrew McConaghie
  
Eye Test
Roche is aiming to add to Vabysmo's existing approvals in wet age-related macular degeneration and diabetic macular edema (DME). • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D